Emergent BioSolutions Announces Positive Phase 1b Otlertuzumab Results in Combination with Rituximab in People with CLL

- Emergent BioSolutions

today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in people with previously untreated chronic lymphocytic leukemia (CLL) (Study 16009). Data from the first cohort to have completed enrollment, presented during the American Society of Hematology annual meeting, showed that the combination was active and well tolerated. Otlertuzumab is a humanized anti-CD37 monospecific protein therapeutic, built on Emergent's ADAPTIRTM (modular protein technology) platform, that targets the CD37 signaling pathway involved in B-cell malignancies such as CLL, non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and other cancers of the blood.